EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Phase I study of zoledronic acid combined with escalated doses of interleukine‐2 for early in vivo generation of Vγ9Vδ2 T ‐cells after haploidentical stem cell transplant with posttransplant cyclophosphamide

Maxime Jullien iD, Thierry Guillaume, Amandine Le Bourgeois, Pierre Peterlin iD, Alice Garnier, Marion Eveillard iD, Yannick Le Bris iD, Simon Bouzy, Benoît Tessoulin iD, Thomas Gastinne, Viviane Dubruille, Cyrille Touzeau und 10 weitere

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27191 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Maxime Jullien und 21 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Nantes University Hospital, Nantes, France. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Centre Hospitalier Universitaire de Nantes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The presence of donor Vγ9Vδ2 T‐cells after haploidentical hematopoietic stem cell transplant (h‐HSCT) has been associated with improved disease‐free survival. These cells kill tumor cells in a non‐MHC restricted manner, do not induce graft‐versus‐host disease (GVHD), and can be generated by stimulation with zoledronic acid (ZA) in combination with interleukin‐2 (IL‐2). This monocentric phase I, open‐label, dose‐escalating study (ClinicalTrials.gov: NCT03862833) aimed at evaluating the safety and possibility to generate Vγ9Vδ2 T‐cells early after h‐HSCT. It applied a standard 3 + 3 protocol to determine the maximum tolerated dose (MTD) of increasing low‐doses of IL‐2 (5 days [d] per week, 4 weeks) in combination with a single dose of ZA, starting both the first Monday after d + 15 posttransplant. Vγ9Vδ2 T‐cell monitoring was performed by multiparameter flow cytometry on blood samples and compared with a control cohort of h‐HSCT recipients. Twenty‐six patients were included between April 2019 and September 2022, 16 of whom being ultimately treated and seven being controls who received h‐HSCT only. At the three dose levels tested, 1, 0, and 1 dose‐limiting toxicities were observed. MTD was not reached. A significantly higher number of Vγ9Vδ2 T‐cells was observed during IL‐2 treatment compared with controls. In conclusion, early in vivo generation of Vγ9Vδ2 T‐cells is feasible after h‐HSCT by using a combination of ZA and repeated IL‐2 infusions. This study paves the way to a future phase 2 study, with the hope to document lesser posttransplant relapse with this particular adaptive immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationGraft vs Host DiseaseHumansInterleukin-2Zoledronic AcidT-LymphocytesCyclophosphamideStem Cell Transplantation

Substanzen

Interleukin-2Zoledronic AcidCyclophosphamide

Autor:innen und Institutionen

  • Hematology Department, Nantes University Hospital, Nantes, France.
  • Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France.
  • LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France.
  • Hematology Biology, Nantes University Hospital, Nantes, France.

ORCID-Profile: Maxime Jullien, Pierre Peterlin, Marion Eveillard, Yannick Le Bris, Benoît Tessoulin, Philippe Moreau, Patrice Chevallier

Förderung

  • Centre Hospitalier Universitaire de Nantes

Zitieren

APA

Jullien, M., Guillaume, T., Le Bourgeois, A., Peterlin, P., Garnier, A., Eveillard, M., Le Bris, Y., Bouzy, S., Tessoulin, B., Gastinne, T., Dubruille, V., Touzeau, C., Mahé, B., Blin, N., Lok, A., Vantyghem, S., Sortais, C., Antier, C., Moreau, P., …, & Chevallier, P. (2024). Phase I study of zoledronic acid combined with escalated doses of interleukine‐2 for early in vivo generation of Vγ9Vδ2 T ‐cells after haploidentical stem cell transplant with posttransplant cyclophosphamide. American Journal of Hematology. https://doi.org/10.1002/ajh.27191

Vancouver

Jullien M, Guillaume T, Le Bourgeois A, Peterlin P, Garnier A, Eveillard M, et al. Phase I study of zoledronic acid combined with escalated doses of interleukine‐2 for early in vivo generation of Vγ9Vδ2 T ‐cells after haploidentical stem cell transplant with posttransplant cyclophosphamide. American Journal of Hematology. 2024. doi:10.1002/ajh.27191

BibTeX
@article{Jullien2024,
  author = {Jullien, Maxime and Guillaume, Thierry and Le Bourgeois, Amandine and Peterlin, Pierre and Garnier, Alice and Eveillard, Marion and Le Bris, Yannick and Bouzy, Simon and Tessoulin, Benoît and Gastinne, Thomas and Dubruille, Viviane and Touzeau, Cyrille and Mahé, Béatrice and Blin, Nicolas and Lok, Anne and Vantyghem, Sophie and Sortais, Clara and Antier, Chloé and Moreau, Philippe and Scotet, Emmanuel and Béné, Marie C and Chevallier, Patrice},
  title = {Phase I study of zoledronic acid combined with escalated doses of interleukine‐2 for early in vivo generation of Vγ9Vδ2 T ‐cells after haploidentical stem cell transplant with posttransplant cyclophosphamide},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27191}
}
Kostenlos starten →